Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 02:09 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Daunorubicin or Idarubicin With Cytarabine Plus Quizartinib vs Physician's Choice in Newly Diagnosed FLT3-ITD+ AML
NCT04676243 · University Hospital Heidelberg · PHASE3 · withdrawn · last registry update 2022-05-25 · Acute myeloid leukemia · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Study turned out no longer feasible” | Open Targets' class: study design | Registry record, University Hospital Heidelberg |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against CSF1R in acute myeloid leukemia within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2022-10-05Results posted on the registry: Daiichi Sankyo, Chemotherapy + Quizartinib (NCT02668653)
- 2022-09-15Also stopped (terminated): Prof. Dr. Richard F Schlenk, MRD-triggered arm + Prophylactic Arm (NCT03989713)
- 2022-05-20Results posted on the registry: Daiichi Sankyo, Quizartinib + Milademetan (NCT03552029)
- 2022-05-20Also stopped (terminated): Daiichi Sankyo, Quizartinib + Milademetan (NCT03552029)
- 2021-12-02Results posted on the registry: OHSU Knight Cancer Institute, Edicotinib (NCT03557970)
- 2021-12-02Also stopped (terminated): OHSU Knight Cancer Institute, Edicotinib (NCT03557970)
- 2021-08-19Results posted on the registry: Daiichi Sankyo Co., Ltd., Quizartinib + Cytarabine (NCT02834390)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision